GlassScriptPhysician profile
Punnam Stephan
NPI 1104245984
$2,519.72
in general payments reported to CMS, 2019-2025
26 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $645 · 2022: $465 · 2023: $476 · 2024: $480 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,409.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $594.21 | 2021-2025 | Arexvy, Shingrix, Bexsero |
| Novo Nordisk INC | $494.21 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $204.21 | 2021-2022 | |
| Dexcom, INC. | $193.12 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $176.53 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $111.11 | 2022-2025 | |
| Amgen INC. | $97.69 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $80.63 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $77.02 | 2022-2025 | Farxiga |
| Biohaven Pharmaceuticals, INC. | $65.72 | 2021 | |
| Pfizer INC. | $64.38 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.69 | 2022 | |
| Paratek Pharmaceuticals, INC. | $40.13 | 2022 | |
| Idorsia Pharmaceuticals US INC | $34.25 | 2023 | Quviviq |
| Corcept Therapeutics | $31.88 | 2025 | Korlym |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $23.82 | 2024 | Watchman Flx |
| Dynavax Technologies Corporation | $23.56 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.28 | 2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.77 | 2023 | |
| Biogen, INC. | $18.26 | 2021 | |
| Esperion Therapeutics, INC. | $18.04 | 2024 | Nexletol |
| Sanofi Pasteur INC. | $17.99 | 2025 | |
| Kyowa Kirin, INC. | $17.65 | 2025 | |
| Merck Sharp & Dohme LLC | $14.61 | 2021 | |
| Genentech USA, INC. | $14.44 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Punnam Stephan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.